HALO — Halozyme Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $4.91bn
- $6.07bn
- $829.25m
- 89
- 39
- 70
- 72
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 196 | 268 | 443 | 660 | 829 |
Cost of Revenue | |||||
Gross Profit | 150 | 224 | 362 | 521 | 637 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 264 | 123 | 188 | 395 | 492 |
Operating Profit | -67.6 | 144 | 255 | 265 | 338 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -72.3 | 129 | 249 | 249 | 348 |
Provision for Income Taxes | |||||
Net Income After Taxes | -72.2 | 129 | 403 | 202 | 282 |
Net Income Before Extraordinary Items | |||||
Net Income | -72.2 | 129 | 403 | 202 | 282 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -72.2 | 129 | 403 | 202 | 282 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.501 | 0.912 | 2.84 | 1.58 | 2.11 |